Main Conference Day 3Wednesday, 17 December 2025 - PT (Pacific Time, GMT-08:00)

We are developing dual-payload ADCs that enable delivery of two different payloads simultaneously to the tumor with the goal of enhancing therapeutic efficacy and overcoming resistance mechanisms. Leveraging our cell-free platform, we precisely control payload placement and ratio to optimize efficacy. Preclinical data demonstrate superior efficacy in vitro and in vivo over single-payload ADCs, with favorable pharmacokinetics, stability, and safety.

PIP is a versatile targeting peptide that binds selectively to multiple tumor-associated targets, a unique feature enabling payload delivery to virtually any solid tumor. This presentation focuses on the development of PIP-Drug Conjugates, their efficacy and safety, and how PIP’s multi-specific targeting overcomes resistance seen with conventional single-antigen targeting ADCs.

Radiotherapy remains a cornerstone of cancer treatment, yet its efficacy is often limited by normal tissue toxicity and tumor resistance. This talk will highlight a translational strategy to enhance radiotherapy by leveraging antibody-drug conjugates (ADCs) for targeted delivery of cytotoxic agents. I will present preclinical data demonstrating how ADCs directed against radiation-inducible tumor antigens potentiate tumor response, offering a precision-based approach to improve outcomes in solid tumors.

We are investigating unique payloads by exploring agents that target cancer cell dependencies/vulnerabilities, or that have known or assumed safety liabilities or poor physicochemical properties that would benefit from delivery via antibodies. We will discuss early achievements in the development of these more targeted ADCs.